Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.51 |
| ▸ | NCF1 | P14598 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8687400 | 0.79 | DRD4 (0.45) | ADRB1HTR7HTR2AHTR3AHTR3E | |
| SCHEMBL6862878 | 0.78 | HTR6 (0.51) | ADRB1NCF1ADRB2HTR7HTR6 | |
| SCHEMBL8687729 | 0.77 | MAPT (0.49) | ADRB1HTR3AHTR3EHTR3BTSHR | |
| SCHEMBL6637856 | 0.76 | HTR6 (0.64) | ADRB1NCF1HTR7HTR6HTR2A | |
| SCHEMBL3274856 | 0.75 | HTR6 (0.45) | ADRB1NCF1ADRB2HTR7HTR6 | |
| SCHEMBL13324655 | 0.75 | HDAC6 (0.50) | HTR3AHTR1A | |
| SCHEMBL8687616 | 0.75 | CYP2C9 (0.64) | HTR7HTR6HTR2ACYP1A2HTR1A | |
| SCHEMBL8687610 | 0.74 | NPY5R (0.40) | ADRB1NCF1ADRB2HTR7HTR2A | |
| SCHEMBL3289568 | 0.73 | HTR2A (0.50) | ADRB1NCF1ADRB2HTR7HTR6 | |
| SCHEMBL428165 | 0.73 | NCF1 (0.69) | ADRB1NCF1ADRB2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684837-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2025-09-11 | — | — | US | disclosed |
| EP-3541790-B1 | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION | UNIV TEMPLE (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210238189-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3541790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093818-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | ADRB1 113/4885NCF1 4098/4885ADRB2 97/4885 |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | ADRB1 120/4885NCF1 3964/4885ADRB2 113/4885 |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | ADRB1 113/4885NCF1 4098/4885ADRB2 97/4885 |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | ADRB1 120/4885NCF1 3964/4885ADRB2 113/4885 |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | ADRB1 120/4885NCF1 3964/4885ADRB2 113/4885 |
| US-20210238189-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | ADRB1 113/4885NCF1 4098/4885ADRB2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.